[Haisco: All indications of cyclopofol injection have been included in the national medical insurance catalog].
Haisco recently announced that all the indications of cyclopofol injection developed by it have been included in the national medical insurance catalog. Cyclopofol injection is a widely used drug in clinical practice, which can be used for anesthesia induction and maintenance, and has the characteristics of rapid onset and long-lasting effect. The inclusion in the National Medical Insurance Catalogue will enable more patients who need it to enjoy the advantages and convenience of this drug. This is also one of the important achievements of Hisco in the medical field. For Hisco, this good news will undoubtedly further promote the market expansion and influence of its products.
Insai Group: At least 4 short dramas produced by subsidiaries will be released next year
In an institutional survey, Insai Group said that the company is laying out new businesses in a timely manner. The company's subsidiary, Yingxing World, has successfully produced the short drama "Attack on Secretary Kim", which has received a good response in the market. It is expected that at least 4 short dramas produced by Yingxing World will come out next year. In addition, Shadow World is also working with external strategic partners to develop an interactive story game. The game is expected to launch in the first quarter of 2024. In addition, the company is also in contact with the domestic head short drama platform and excellent short drama business team to improve the feasibility of strategic cooperation.
*Pharmaceutical: The company's product neo-activin continues to be included in the National Medical Insurance Drug List
*The pharmaceutical industry has recently learned that its product neo-activin has been continuously included in the national medical insurance drug list. This news is undoubtedly a positive development for ** Pharmaceutical. As one of the company's main products, the inclusion of Neoactivin in the National Medical Insurance Drug List will further expand its market share and bring more sales opportunities to the company. This will enable more patients to enjoy the benefits of Neovizol and access to more affordable medical coverage.
Hongri Pharmaceutical: The company's product Xuebijing Injection continues to be included in the National Medical Insurance Drug Catalog
Hongri Pharmaceutical recently announced that the company's product Xuebijing Injection has been included in the National Medical Insurance Drug List. This news is of great significance to the company. Xuebijing injection is one of the company's key products, and its inclusion in the National Medical Insurance Drug List will help improve the market competitiveness and sales of the product.
Three domestic new crown drugs were included in the medical insurance catalog, and some products were reduced to 479 yuan box].
In the new version of the medical insurance catalog, three domestic new crown drugs approved for marketing this year have been included in the medical insurance. This means that these drugs have officially become covered by medical insurance. In March this year, the National Health Insurance Administration issued the "Notice on Improving the Formation Mechanism of New Crown Drugs" and Implementing Classified Management, which stipulates that a number of new crown drugs can enjoy temporary medical insurance payment.
Dizhe Pharmaceutical: The Chinese registration study of Shuwozhe was published in The Lancet Respiratory Medicine].
Dizhe Therapeutics recently published the results of the Chinese registration study of Suwozhe in the journal "Lancet Respiratory Medicine".
Kunpeng Project